Article Text
Statistics from Altmetric.com
We appreciate the interest of Dr Schulze-Koops and colleagues in our article.1 The role of the inflammatory rheumatic diseases (IRDs), their therapies and other potential factors in the risk of SARS-CoV-2 infection and course of COVID-19 disease are a topic in a constant update. In this sense, we consider that our study provides additional evidence in patients with IRD regarding susceptibility to moderate-severe infection related to COVID-19.2
It is important to note that SARS-CoV-2/COVID-19 is a very changing epidemiological scenario. Our manuscript is a real-world longitudinal study performed during the period of maximum health emergency due to the COVID-19 pandemic in Madrid, the epicentre of the outbreak in Spain. We included all patients …
Footnotes
Handling editor Josef S Smolen
Twitter @Fergutbe2001
Contributors All authors have provided the initial draft, led the discussion and corrected the text.
Funding This work was supported by the Instituto de Salud Carlos III (ISCIII), Ministry of Health, Spain (CP16/00916, PI18/01188 and RD16/0012/0014) and co-funded by el Fondo Europeo de Desarrollo Regional (FEDER). The funders had no role in study design, data collection, analysis, manuscript preparation or decision to publish.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.
Provenance and peer review Commissioned; internally peer reviewed.